In a randomized trial conducted in five countries, a 2-month drug regimen was found to be non-inferior to the standard 6-month treatment.
Also, Shionogi announces that the novel antibiotic cefiderocol is now available in Denmark for treating infections caused by gram-negative bacteria in patients with limited treatment options.
There are currently 16 vaccine candidates in clinical development, but progress has been constrained by lack of funding and attention.
The regimen was recently recommended by the WHO for treating patients with drug-resistant TB.
The pact will help lower the cost of two shorter treatment regimens for drug-resistant tuberculosis, broadening access.
Despite the milestone, funding remains far short of what's needed, according to a new report.
The shorter 6-month regimen could save enough to supply 400,000 people with almost a year's worth of treatment.
The findings suggest the drug could be part of a shorter and simpler tuberculosis treatment regimen.
A study today in BMC Medicine highlights the toll that the COVID-19 pandemic has taken on the diagnosis of tuberculosis (TB) in high-burden countries, particularly in vulnerable populations.
A clinical trial conducted in seven countries found that two shortened, bedaquiline-containing regimens had superior efficacy in treating rifampicin-resistant tuberculosis (TB) compared with a 9-month injectable-containing regimen, with fewer cases of hearing loss, investigators reported today in The Lancet.
